New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs Vialox

Orforglipron vs Vialox

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Skin & CosmeticAnti-Aging & Longevity
Vialox
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Vialox is a synthetic pentapeptide that mimics the activity of conotoxin from cone snails, acting as an antagonist of nicotinic acetylcholine receptors at the neuromuscular junction. Similar to Syn-Ake but derived from cone snail venom biochemistry, it reduces facial muscle contraction to smooth expression wrinkles.
Half-Life
~12 hours (once-daily oral dosing)
Not applicable (topical; effect duration hours)
Admin Route
Oral
Topical
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
0.005-0.05% in formulation
Frequency
Once daily
Twice daily
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Reduces dynamic wrinkles from repetitive facial expressions
  • Reversible muscle-relaxing effect without injection
  • Smooths forehead, periorbital, and perioral lines
  • Complementary to collagen-stimulating peptides
  • Well-studied tolerability in cosmetic concentrations
  • Can be combined with Syn-Ake for dual conotoxin/viper venom effect
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Generally very well-tolerated topically
  • Rare contact sensitivity or mild irritation
  • No clinically significant systemic neuromuscular effects at cosmetic doses
Stacks With